Oncolytic Viral Therapy
15847
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15847,qode-quick-links-1.0,,qode-title-hidden,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

LEARN ABOUT OUR TECHNOLOGIES

Our mission is to create
a single shot to cure cancer
using engineered viruses
VSV Platform

EXPLORE

Vyriad is a clinical stage bio-pharmaceutical company focused on helping people with cancer.

Our attention is focused on curing cancer, so people can lead happy and healthy lives.  We develop smart viral-based therapies to destroy tumors and collaborate with Mayo Clinic and other partners to develop our technologies.

pet-scan

ACTIVE CLINICAL TRIALS

Vyriad is currently conducting clinical trials with a number of medical institutions, including Mayo Clinic and University of Arkansas.  Our viruses are being tested in several Phase I and Phase II clinical trials in multiple disease indications.

STRATEGICALLY ENGINEERED TUMOR-KILLING VIRUSES

Our viruses were originally developed in the laboratories of Drs Stephen Russell and Kah Whye Peng at Mayo Clinic and Dr Glen Barber at University of Miami.  Vyriad maintains a vibrant clinical pipeline by continuously creating and testing cancer-fighting viruses engineered in different ways, and combined with various drugs, to destroy cancer cells directly as well as harness and enhance the body’s natural tumor-killing immune responses

partnership-group

STRIVING FOR SYNERGY

Collaboration and combination therapy are critical drivers of success in cancer therapy.  For this reason, we pursue partnerships to identify, develop and secure innovations in oncolytic therapy. We seek synergistic relationships that fit our long-term goals and offer a shared vision for an effective cancer therapy.